FADS1 and acute myeloid leukemia: Interestingly, a recent study revealed that genetic or pharmacologic inhibition of fatty acid desaturases 1 and 2 (FADS1 and FADS2) synergized with venetoclax and azacitidine treatment and significantly reduced the viability of primary AML samples [14, 167].